Effects of Allopurinol on the Progression of Chronic Kidney Disease.

Sunil V BadveElaine M PascoeAnushree TikuNeil BoudvilleFiona G BrownAlan CassPhilip ClarkeNicola DalbethRichard O DayJanak R de ZoysaBettina DouglasRandall FaullDavid C HarrisCarmel M HawleyGraham R D JonesJohn KanellisSuetonia C PalmerVlado PerkovicGopala K RanganDonna ReidlingerLaura RobisonRobert J WalkerGiles D WaltersDavid W Johnsonnull null

Published in: The New England journal of medicine (2020)

In patients with chronic kidney disease and a high risk of progression, urate-lowering treatment with allopurinol did not slow the decline in eGFR as compared with placebo. (Funded by the National Health and Medical Research Council of Australia and the Health Research Council of New Zealand; CKD-FIX Australian New Zealand Clinical Trials Registry number, ACTRN12611000791932.).

Keyphrases

chronic kidney disease
clinical trial
end stage renal disease
small cell lung cancer
healthcare
epidermal growth factor receptor
tyrosine kinase
open label
placebo controlled